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ABSTRACT 
 Two new simple, sensitive, rapid, accurate and reproducible 
methods (UV-spectrophotometric and ion pair 
chromatography) have been developed for simultaneous 
estimation of valsartan (VAL) and hydrochlrothiazide 
(HCTZ) from their tablet dosage form. The first method 
involves multiwavelength spectrophotometric method 
(Method 1) in which interference of HCTZ at 245nm 
(wavelength for estimation of VAL) was removed by 
recording absorbance difference at 245nm and 301 nm 
whereas HCTZ was estimated directly from its absorbance at 
316 nm at which VAL shows no absorbance. Linearity of the 
response was demonstrated by VAL in the concentration 
range of 5-45 g/ml with a square correlation coefficient (r2) 
of 0.9998. Linearity of the response was demonstrated by 
HCTZ in the concentration range of 2-18 g/ml with a square 
correlation coefficient (r2) of 0.9994.  The second method 
utilizes ion pair chromatography (Method 2) on a HIQ sil 
ODS column (250 mm* 4.6 mm i.d.) using methanol: 0.0025 
M orthophosphoric acid: (70:30 by volume) having pH 4.6: 
0.1% hexane sulphonic acid as mobile phase with UV 
detection at 259nm over concentration range for VAL is 240-
0 µg/ml, and for HCTZ is 75-0µg/ml. Losartan potassium 
was used as the internal standard. The suggested procedures 
were checked using laboratory prepared mixtures and were 
applied successfully for the analysis of their tablet dosage 
form. The results of analysis were statistically analysed. Both 
the methods were validated as per ICH Q2B guidelines. 
  
KEYWORDS: valsartan, hydrochlrothiazide, Losartan 
Potassium Ultraviolet spectrophotometry, Multiwavelength 
method, RP-HPLC, Validation 
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1. INTRODUCTION 
Valsartan (VAL) is angiotensin II receptor blocker. 
Chemically VAL is N-[-P-(0-1 H- Tetrazole-5yl phenyl) 
Benzyl]-N-Valeryl -L-Valine 1.Several analytical methods 
such as liquid chromatography-tandam mass sprectrometry 2, 
micellar electrokinetic chromatographic method 3, capillary 
zone electophoresis 4, pKa 5,  HPLC 6-7 determination 
methods are reported for estimation of valsartan from their 
respective single dosage forms. Ratio spectra derivative, 
inverse least square technique 8, and HPLC by using buffer, 
First derivative spectrophotometry 9, has been reported for 
simultaneous estimation of valsartan and hydrochlorothiazide 
from their combined dosage forms.  
 
Hydrochlrothiazide (HCTZ) chemically known as 
6-chloro -3,4 dihydro -2H,-1,2,4,Benzothiadiazine-7-     
Sulfonamide,1,1-dioxide, is a  diuretic and is useful in the 
treatment of mild to moderate essential hypertension 10.The 
drug is mentioned in Martindale; The Extra Pharmacopoeia11. 
A survey of literature revealed different analytical methods 
including Gas chromatography-mass spectrometric method 
12, electrochemical 13, time resolved chemiluminence 14, 
micellar electrokinetic method15, High Performance Liquid 
Chromatography16-18,  Capillary electrophoresis4 etc. Few 
spectrophotometric methods have also been reported19-20. Fix 
dose combination containing VAL and HCTZ is available in 
tablet dosage form in market. In the present work an attempt 
has been made to develop and validate a simple, sensitive and 
reproducible spectrophotometric method and ion pair 
chromatographic method with greater precision, accuracy, 
and sensitivity for the quality control and routine analysis of 
VAL and HCTZ in tablet dosage form.                                   
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Valsartan                                                     Hydrochlorothiazide 
                                C24H29N5O3                                              C7H8Cl N3O4 S2 
Mol. Wt. 435.5                                               Mol. Wt. 297.7 
 
Chemical structure of valsartan and hydrochlorthiazide 
 
2. EXPERIMENTAL  
2.1 Apparatus 
a) A PC based Jasco V-530 recording 
spectrophotometer with spectral bandwidth (resolution) of 2 
nm and Wavelength accuracy ± 0.3 nm (with automatic 
wavelength correction) was employed for all measurements 
using a matched pair of 10mm quartz cell.b) The HPLC 
system was a PC based Jasco series comprising of a pump 
PU-2080 and a UV-2070 detector. Manual injections were 
carried out using a Rheodine injector with a fixed 20 µl 
external loop. The chromatographic separations were 
performed on a 5 µm HIQ sil ODS column (250 mm x 4.6 
mm i.d.), operating at ambient temperature, using a mobile 
phase consisting of methanol: 0.0025 M orthophosphoric 
acid (70:30 by volume) having pH 4.6: 0.1% hexane 
sulphonic acid. c) Shimadzu AY 120 analytical balance was 
used for weighing. d) PCi Ultrasonicator was used for 
sonication.
2.2. Materials   
2.2.1. Pure samples 
Valsartan and hydrochlorothiazide were kindly 
supplied by Lupine pharma Ltd., Pune and Macloide pharma 
Ltd., Mumbai, India. respectively. Their purity was found to 
be 100.65 ± 0.71 and 99.23 ± 0.82 respectively.   
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2.2.2. Market samples 
Marketed sample of VAL and HCTZ (Valent H) in 
their combined tablet dosage form. of Merck Limited 
Aurangabad, India. Batch No. A 6011WB was used for 
analysis. Each tablet contains 80mg of VAL and 12.5 mg of 
HCTZ. 
2.2.3. Chemical and reagents 
For spectrophotometric work methanol (Loba 
chemie Pvt. Ltd. Mumbai, India) of pure analytical grade. For 
HPLC work double distilled water, Methanol and 
Orthophosphoric acid, and hexane sulphonic acid sodium salt 
(Spectrochem Pvt. Ltd. Mumbai,India) were of HPLC grade. 
2.3. Preparation of standard and sample solutions  
2.3.1. Standard stock solutions 
2.3.1.1. For spectrophotometric method  
VAL and HCTZ standard stock solution (1000 µg. 
m l – 1 each of VAL and HCTZ) were prepared by weighing 
accurately 100 mg of VAL and HCTZ separately into two 
100-ml volumetric flasks and dissolved in 40 ml of methanol. 
The mixture was sonicated for 10 minutes and volume was 
made up to 100 ml with the same solvent. 
2.3.1.1. For HPLC method 
Standard stock solutions containing VAL and 
HCTZ were prepared by transferring 100 mg of VAL into 50 
ml volumetric flask and dissolved in 30ml of methanol and 
ultrasonicated for 10 minutes. The final volume of the 
solution was made up to 50 ml with methanol to get stock 
solutions containing 2000 μg ml-1 of VAL. 100 mg of HCTZ 
separately into 100 ml volumetric flasks and dissolved in 
40ml methanol and ultrasonicated for 10 minutes. The final 
volume of the solution was made up to 100 ml with methanol 
to get stock solutions containing 1000 μg ml-1 of HCTZ. 
Losartan potassium (LP) was selected as an internal 
standard. Standard stock solution containing LP was prepared 
by dissolving 10 mg of LP in 40 ml of methanol in a 100 ml 
volumetric flask. It was then ultrasonicated for 10 minutes 
and then final volume of solution was made up to 100 ml 
with methanol to get 100 μg ml-1 of LP. 
2.3.2. Working solutions 
One ml of the stock solutions of VAL and HCTZ 
standard stock solution were transferred in two separate 
100ml volumetric flasks and diluted to the mark with 
methanol to get a final concentration of 100µg/ml each of 
VAL and HCTZ for the spectrophotometric work. For HPLC 
method, 50 ml of the Standard stock solutions containing 
VAL transferred into separate 100-ml volumetric flasks and 
10 ml of HCTZ were transferred into separate 100-ml 
volumetric flasks and diluted to the mark with mobile phase 
to get a final concentration of 1000 µg/ml of VAL and 100 
µg/ml HCTZ.  
 
2.4. Laboratory prepared mixtures  
2.4.1. For spectrophotometric method 
Accurate aliquots of VAL and HCTZ were 
transferred from working solutions (100 µg ml– 1) into a 
series of seven 10-ml volumetric flasks and volume was 
made up to the mark with methanol. Ten mixed standard 
solutions containing concentrations of 0, 5, 10, 15, 20, 25, 30, 
35, 40, and 45 µg/ml of VAL and 0, 2, 4, 6, 8, 10, 12, 14, 16, 
and 18 µg/ml of HCTZ were obtained. 
2.4.2. For HPLC method 
In to a series of six 10 ml volumetric flasks, 2.4 to 
0 ml of VAL (1000μg ml-1) and 0 to 7.5 ml of HCTZ solution 
(100 μg ml-1) was pipetted and to each flask 2 ml of (100 μg 
ml-1) of LP as internal standard was added and then final 
volume of all the solutions was made up to 10 ml with 
mobile phase. Seven mixed standard solutions containing 
concentrations of 240, 200, 160, 120, 80,40, and 0 µg/ml of 
VAL and 0,12.5, 25, 37.5, 50, 62.5, and 75 µg/ml HCTZ and 
20 µg/ml of LP were obtained. 
2.5. Procedures 
2.5.1. Spectrophotometric method 
For estimation of VAL, multiwavelength 
spectrophotometric method employing 245 nm and 301nm as 
analytical wavelengths was used; the two wavelengths were 
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chosen to eliminate interference of HCTZ at the sampling 
wavelength of VAL. For estimation of HCTZ, 316 nm was 
selected as the analytical wavelength, as VAL shows no 
absorption at this wavelength. 
 
 
2.5.1.1. Linearity 
Absorption spectras of ten mixed standard 
solutions prepared as above containing concentrations of 0, 5, 
10, 15, 20, 25, 30, 35, 40, and 45µg/ml of VAL and 18, 16, 
14, 12, 10, 8, 6, 4, 2, and 0 µg/ml of HCTZ were recorded in 
the range of 200-400 nm with scanning speed of 1000 nm 
min– 1, 1.0 nm data pitch and 2 nm bandwidth against 
methanol as blank. Calibration curve for VAL was 
constructed against concentration by taking absorbance 
differences at 245 nm and 301 nm from the spectra of mixed 
standards whereas the calibration curve for HCTZ was 
plotted against concentration using absorbance at 316 nm and 
the regression equations were generated. 
2.5.1.2. Assay of laboratory-prepared mixtures 
  Absorption spectras of different laboratory-
prepared mixtures containing different concentrations of the 
two drugs were recorded. For the determination of 
concentration of the VAL absorbance difference was 
recorded at 245 nm and 301 nm whereas for determination of 
concentration of HCTZ absorbance was noted at 316 nm. The 
concentration of each drug was calculated from the 
corresponding regression equation. 
2.5.1.3. Assay of marketed pharmaceutical preparation 
(Valent H tablet) 
A commercially available tablet formulation 
containing VAL 80mg and HCTZ 12.5mg was analyzed 
using this method. Twenty tablets were accurately weighed 
and average weight was calculated.  
These tablets were ground to a fine powder and an 
accurately weighed tablet powder equivalent to 10mg of 
VAL was transferred to a 100 ml volumetric flask and to this 
2 mg of pure HCTZ was added. 60ml of methanol was added 
to the flask. The solution was sonicated for 10 min. at 25 0C. 
The solution was then filtered through Whatmann filter paper 
No.41 and the volume was made up to 100 ml with methanol. 
The solution was analysed using the method described under 
assay of laboratory-prepared mixtures (as in 2.5.1.2.).  
2.5.2. HPLC method 
2.5.2.1. Linearity 
Accurate aliquots equivalent to 240-0 µg/ml of 
VAL  (1000 µg. ml-1 )  and 0-75 µg/ml of HCTZ (100 µg. ml-
1 )  from their working solutions were transferred into one set 
of series of six 10 ml volumetric flasks. To each flask 2 ml of 
(100 μg. ml-1) of LP as internal standard was added and 
completed to volume with the mobile phase. A 20 μl of 
sample solution was injected into the chromatographic 
system using fixed volume loop injector and chromatograms 
were recorded. The flow rate was maintained at 1 ml min-1 at 
ambient temperature and the elluents were monitored at 259 
nm. The separation was done on a C18 column using 
methanol: 0.0025 M orthophosphoric acid (70:30 by volume) 
having pH 4.6: 0.1% hexane sulphonic acid. Calibration 
curves for both VAL and HCTZ were plotted and the 
corresponding regression equations were generated. 
2.5.2.2. Assay of laboratory-prepared mixtures 
Chromatograms of different laboratory-prepared 
mixtures containing different concentrations of the two drugs 
were recorded. The chromatographic conditions were applied 
for each laboratory-prepared mixtures and the concentrations 
of VAL and HCTZ were calculated by substituting in the 
regression equations. 
2.5.2.3. Assay of marketed pharmaceutical preparation 
(Valent H tablet) 
From the triturate of 20 tablets, an amount 
equivalent to 80 mg of VAL and 12.5 mg of HCTZ  was 
weighed, transferred to a 50 ml volumetric flask and 
dissolved in 30 ml methanol. It was then ultrasonicated for 10 
minutes. The solution was filtered through 0.22 μ membrane 
filter and then final volume of the solution was made up to 50 
with methanol. Appropriate aliquots within the Beer’s law 
limit were withdrawn into 10 ml volumetric flasks and to 
each of them 2ml of (100 μg. ml-1) of LP as internal standard 
was added. The volume was made up to the mark with 
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methanol and analyzed by the proposed method using the 
procedure described under linearity (2.5.2.1.). The 
concentration of VAL and HCTZ present in the sample 
solution was calculated by using regression equation 
generated from calibration curve of respective drugs.   
3. Results and Discussion 
The development of an analytical method for 
simultaneous estimation of drugs without previous chemical 
separation in multicomponent pharmaceutical formulations 
has received considerable attention in recent years because of 
their importance in quality control of drugs and drug 
products.  
This work is devoted for the analysis of VAL and 
HCTZ which are available together in the from of tablets. 
Therefore the aim of this work was to develop simple 
analytical methods for the simultaneous determination of 
VAL and HCTZ. This was achieved by development of one 
multiwavelength spectrophotometric and one ion pair 
chromatographic method. The methods were validated 
according to International Conference on Harmonization 
Q2B guidelines [39] for validation of analytical procedures in 
order to determine the linearity, sensitivity, precision and 
accuracy for each analyte. Nine point calibration curves were 
generated with appropriate volumes of working standard 
solutions for UV and six point calibration curves were 
generated with appropriate volumes of working standard 
solutions for HPLC methods. 
  
  
 Spectrophotometric method 
Multiwavelength absorption spectrophotometric 
method was developed for analysis of VAL and HCTZ. The 
method utilizes ten mixed standard solutions involving 
scanning at 245 nm, 301 nm and 316 nm as sampling 
wavelengths. From the overlain spectra it was noted that 
there is no wavelength over the scanning range of 200 to 400 
nm where VAL can be accurately quantified without 
substantial interference of HCTZ. Thus quantification of 
VAL was achieved by taking the absorbance difference at 
245 nm and 301nm. HCTZ was directly estimated at 316 nm 
without interference of VAL. Overlain spectra of individual 
drugs and mixed standards are shown in Fig. 1 and 2. 
Regression analysis for multiwavelength 
spectrophotometric method was carried out (Table I) and the 
linearity of the calibration graph and adherence of the method 
to Beer’s law were validated by high value of the correlation 
coefficient (r ), 0.9998and 0.9994 for VAL and HCTZ 
respectively. The results of Quantitative determination of 
VAL and HCTZ in tablets were found in good agreement 
with the labeled amount of both the drugs( Table II). In 
addition, coefficient of variation (CV) for the determination 
of VAL and HCTZ was 0. and 0.  
Closeness of the amount found to the labelled 
amount and the low coefficient of variation value showed 
that the proposed method was accurate and precise. Recovery 
study conducted by the proposed spectrophotometric method 
was performed by spiking the powdered tablets with 
appropriate amounts of stock solution. The results of the 
recovery analysis are also represented in Table III. High 
recoveries, 98.77 ± 0.42 and 101.07 ± 1.02 and low standard 
deviation confirmed the suitability of the proposed method 
for the determination of VAL and HCTZ respectively in 
tablet formulation.  
Both precision and accuracy were determined with 
standard quality control samples (in addition to calibration 
standards) prepared in triplicates at different concentration 
levels covering the entire linearity range. Precision is the 
degree of repeatability of an analytical method under normal 
operational conditions. The precision of the assay was 
determined by repeatability (intra-day) and intermediate 
precision (inter-day) and reported as %R.S.D. The 
intermediate precision was studied by comparing the assays 
on 2 Different days and the results documented as standard 
deviation and %R.S.D. Accuracy is the percent of analyte 
recovered by assay from a known added amount. Data from 
six determinations over four concentration levels covering 
the specified range was determined. Results of inter-day and 
intra-day precision are given in table IV. The repeatability of 
the method was determined by assaying six sample solutions. 
(Given as Table V). 
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Fig.1  Overlain spectra of VAL and HCTZ. 
 
 
 
 
 
Fig.2 Overlain spectra of mixed standards of VAL and HCTZ. 
 
 
 
 
 
VAL 
HCTZ 
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Fig.3 Calibration curve for VAL. 
 
 
 
 
 
Fig.4 Calibration curve for HCTZ. 
 
 
 
 
Fig. 5 Chromatogram of Physical mixture. 
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The method specificity was assessed by comparing 
the UV spectra obtained from the drug and the most 
commonly used excipients mixture with those obtained from 
blank (excipients solution in methanol without drug). The 
excipients chosen are the ones used commonly in tablet 
formulation, which included lactose, starch, microcrystalline 
cellulose, PVP, and magnesium stearate. The drug to 
excipient ratio used was similar to that in the commercial 
formulations.The limit of detection (LOD) is defined as the 
lowest concentration of an analyte that an analytical process 
can reliably differentiate from background levels. The limit 
of quantitation (LOQ) is defined as the lowest concentration 
of the standard curve that can be measured with acceptable 
accuracy, precision and variability. The LOD and LOQ were 
calculated as (Given as Table VI)  
LOD = 3.3σ/ S, 
and 
LOQ = 10σ/ S 
Where σ is the standard deviation of the lowest 
standard concentration and S is the slope of the calibration 
curve.An appropriate number of blank samples (6 
determinations) were scanned in the selected range and the 
standard deviations of these responses were calculated. Low 
LOD as 0.36, 0.12 and LOQ as 1.19, 0.41 for VAL and 
HCTZ respectively shows the high sensitivity of the method.  
 
Table I: Optical characteristics (Method 1) 
Parameters VAL HCTZ 
Beer’s law limit(µg/ml) 5-45 2-18 
Molar extinction coefficient ( Moles/lit )   
Correlation coefficient 0.9998 0.9994 
Regression equation (Y*) 
Slope (B) 0.0315 0.0100 
Intercept (A) 0.0059 0.0012 
*Y= A + B*C, where C is the concentration in µg/ml and Y is absorbance unit. 
 
 
TABLE II: Results of Analysis of tablet formulation (Method 1)  
Analyte % Concentration estimated*      (Mean ± S.D.) Coefficient of variance 
VAL 100.81 ± 1.23 1.220 
HCTZ 99.63  ± 1.47 1.476 
     
* Average of six determinations; SD = Standard Deviation. 
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Table III: Recovery studies (Method 1) 
Analyte % Concentration estimated* 
(Mean ± S.D.) 
Coefficient of variance 
VAL 98.77 ± 0.42 0.425 
HCTZ 101.07 ± 1.02 1.009 
*Average of six determinations; SD = Standard Deviation. 
 
 
Table IV: Intraday and Interday precision (Method 1) 
Day % label claim Estimated* 
(Mean ± %RSD) 
Coefficient of 
variance 
% Recovery Estimated*                 
(Mean ± %RSD) 
Coefficient of 
variance 
 VAL HCTZ VAL HCTZ VAL HCTZ VAL HCTZ 
Day 1 101.24 ± 0.71 100.98± 1.25 0.70 1.23 100.33 ± 0.85 101.36 ± 1.37 0.84 1.35 
Day2 99.98± 0.97 100.49 ± 1.46 0.97 1.45 99.27± 0.73 101.71 ± 1.03 0.73 1.01 
Day2 99.77± 0.77 100.68 ± 0.63 0.77 0.62 100.16 ± 0.48 102.31± 0.93 0.47 0.90 
*Average of five determinations; %RSD = % Relative Standard Deviation. 
 
Table V: Repeatibility (Method 1) 
Label claim             
( mg/tab) 
% label claim Estimated *             ( 
Mean ±SD ) 
%Recovery Estimated*                     ( Mean ±SD 
) 
VAL HCTZ VAL HCTZ 
80,12.5 100.15 ± 1.78 100.15± 0.53 100.83 ± 0.47 100.78 ± 0.49 
 
* Average of five determinations; SD = Standard Deviation 
 
 
Table VI: Limit of Detection and Limit of Quantitation (Method 1) 
LOD (µg/ml) * LOQ (µg/ml) * 
VAL HCTZ VAL HCTZ 
0.36 0.12 1.19 0.42 
* Data obtained by six determinations. 
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TableVII: Optical characteristics (Method 2) 
Parameters Values for VAL Values for HCTZ 
Beer’s law limit(µg/ml) 0 – 240 0 – 75 
Correlation coefficient 0.9984 0.9987 
Regression equation (Y*)   
Slope (B) 0.0540 0.0660 
Intercept (A) 0.0110 0.1039 
*Y= A + B*C, where C is the concentration in µg/ml and Y is absorbance unit. 
 
Table VIII: Results of analysis (Method 2) 
Label claim 
VAL & HCTZ 
(mg/tab) 
Label claim Estimated (%)* 
(Mean ± %R.S.D.) 
Recovery Estimated (%)* 
(Mean ± %R.S.D.) 
VAL HCTZ VAL HCTZ 
80, 12.5 99.27 ± 0.77 99.42 ± 1.02 99.47 ± 1.06 98.85 ± 1.07 
*Average of five determinations; R.S.D., Relative Standard Deviation.   
 
Table IX: System Suitability Parameters (Method 2) 
Sr. No. 
Parameters 
 
VAL HCTZ 
1. Theoretical Plates 2017.19 998.37 
2. Assymetry 1.09 1.67 
3. Resolution  3.22  
4. Retention Time in minutes 6.6 2.7 
5. Selectivity 1.35  
6. Calibration Curve (μg/ml) 40-240 12.5-75 
7. Limit of Detection (μg/ml) 3.87 0.15 
8. Limit of Quantitation (μg/ml) 12.77 0.53 
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Ion pair chromatographic method 
A Ion pair chromatographic method was developed 
for estimation of VAL and HCTZ, which can be conveniently 
employed for routine quality control in pharmaceutical 
dosage forms. The chromatographic conditions were 
optimized in order to provide a good performance of the 
assay. In order to affect the simultaneous elution of the two 
components under isocratic conditions, different 
chromatographic conditions (organic modifier, flow rate, 
ionic strength, pH) were investigated. RP-HPLC system 
consisting of HIQ Sil-C18 -10 column (250 mm x 4.6 mm 
i.d.) provided good resolution for separation of VAL and 
HCTZ. The mobile phase for the two drugs was selected 
based on its polarity. Mobile phases containing methanol 
alone or acetonitrile alone were found to elute the two 
compounds unresolved.  Various ratios of Methanol: 
acetonirtrile: water were found to produce the 
chromatograms with very close retention times, poor 
resolution. Mobile phase containing methanol: water (70:30) 
gives tailng effect. Best resolution was achieved at the mobile 
phase composition of methanol:0.0025 M orthophosphoric 
acid (70:30 by volume) having pH 4.6: 0.1% hexane 
sulphonic acid where the peaks of valsartan , 
hydrochlorothiazide, and losartan potassium were clearly 
resolved. Flow rate of 0.5 ml/min. resulted in greater 
retention times and 1.2 ml/min. resulted in very close 
retention times with poor resolution. A flow rate of 1 ml/min. 
resulted in elution of all drugs within 10 minutes.  
 
` The sampling wavelength was selected after 
scanning the drug solutions in the mobile phase having 
concentration of 25 μg ml-1 in the UV range of 200 – 400 nm 
on a UV spectrophotometer. 259 nm was selected as suitable 
wavelength for estimation. Losartan potassium was found to 
be a suitable internal standard for this study under the 
selected chromatographic conditions. Chromatogram of 
physical mixture is shown in Fig.5. while Optical 
characteristics are shown in Table VII. The method was 
specific as none of the excipients interfered with the analytes 
of interest. Hence, the method was suitably employed for 
assaying the commercial formulation containing VAL and 
HCTZ. A six-point calibration curve was constructed with 
working standards and was found linear (r2 ≥0.9984, 0.9987) 
for VAL, HCTZ over their calibration ranges. 
 
The proposed method was applied to the 
determination of VAL and HCTZ in their pharmaceutical 
preparation. The results indicate satisfactory accuracy and 
precision of the method. The statistical data obtained after 
replicate determinations (n = 5) is shown in Table VIII. The 
% recovery ± S. D. (n = 5) of the added VAL and HCTZ was 
99.47 ± 1.06 and 98.85 ± 1.07, respectively (Table VII.). 
System suitability parameters are shown in Table IX. 
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